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Background and Purpose—We sought to determine the predictive value of magnetic resonance imaging measures of
vascular disease (white matter hyperintensities [WMHs], lacunes, microbleeds, and infarcts) compared with atrophy on
the progression of mild cognitive impairment to dementia.
Methods—We included 152 consecutive patients with mild cognitive impairment. Baseline magnetic resonance imaging
was used to determine the presence of medial temporal lobe atrophy and vascular disease (presence of lacunes,
microbleeds, and infarcts was determined, and WMHs were rated on a semiquantitative scale). Patients were followed
up for 21 years.
Results—Seventy-two (47%) patients progressed to dementia during follow-up. Of these, 56 (37%) patients were
diagnosed with Alzheimer’s disease, and 16 (10%) patients were diagnosed with a non-Alzheimer dementia (including
vascular dementia, frontotemporal lobar degeneration, and Parkinson dementia). Converters were older and had a lower
Mini-Mental State Examination score at baseline. On baseline magnetic resonance imaging, patients who progressed to
a non-Alzheimer dementia showed more severe WMHs and had a higher prevalence of lacunes in the basal ganglia and
microbleeds compared with nonconverters. Cox proportional-hazard models showed that, adjusted for age and sex,
baseline medial temporal lobe atrophy (hazard ratio2.9; 95% CI, 1.7 to 5.3), but not vascular disease, was associated
with progression to Alzheimer’s disease. By contrast, deep WMHs (hazard ratio5.7; 95% CI, 1.2 to 26.7) and
periventricular hyperintensities (hazard ratio6.5; 95% CI, 1.4 to 29.8) predicted progression to non-Alzheimer
dementia. Furthermore, microbleeds (hazard ratio2.6; 95% CI, 0.9 to 7.5) yielded a 2-fold increased, though
nonsignificant, risk of non-Alzheimer dementia.
Conclusion—Medial temporal lobe atrophy and markers of cerebrovascular disease predict the development of different
types of dementia in mild cognitive impairment patients. (Stroke. 2009;40:1269-1274.)
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Mild cognitive impairment (MCI) is characterized bymild cognitive deficits not sufficient for a diagnosis of
dementia.1 MCI patients have an increased risk of progression
to dementia, mostly Alzheimer’s disease (AD), although the
risk of another type of dementia is known to be elevated as
well.1–3 Atrophy of the medial temporal lobe (MTA), includ-
ing the hippocampus and entorhinal cortex, is a sensitive
marker for AD. Visual assessment of MTA has been shown to
be a powerful and independent predictor of progression to
dementia in MCI patients.4–6 Additionally, global cortical
atrophy has been demonstrated to be related to progression of
MCI to dementia.7 In contrast to atrophy, the impact of cerebro-
vascular disease on progression to dementia is less clear.
Only a small number of longitudinal studies have exam-
ined the role of vascular disease in MCI patients, and results
have been conflicting.7–11 One study found white matter
hyperintensities (WMHs) to be associated with the risk of
progression from normal cognitive function to MCI, but not
from MCI to dementia.7 This is in line with another report
that did not find an association between cerebrovascular
disease (ie, clinical stroke, extent of WMHs, or presence of
lacunes) and progression of MCI to dementia.9 In contrast,
others did find a relation between WMHs and progression to
AD in MCI patients.10 Nonetheless, this study was small
(n27) and used computed tomography instead of magnetic
resonance imaging (MRI). More recently, a study in a large
sample of MCI patients reported an association between
WMHs and cognitive decline.8 Furthermore, the same group
reported WMHs to be related to an increased risk of vascular
or mixed dementia, but not of AD.11 Expression of vascular
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disease other than WMHs, such as lacunes and microbleeds,
was not taken into account. Little is known about the role of
microbleeds and cognitive function in MCI or dementia
patients, apart from 1 report that found a relation between
microbleeds and cognitive impairment in subcortical vascular
dementia.12 Another study in nondemented patients with
cerebrovascular disease reported a relation between microb-
leeds and executive dysfunction.13 The aim of this study was
to assess the predictive value of MRI measures of both
atrophy and vascular disease, including infarcts, WMHs,
lacunes and microbleeds, with respect to progression of MCI
to dementia.
Subjects and Methods
Patients
We consecutively recruited 152 patients with MCI from the outpa-
tient memory clinic of the Alzheimer Centre of the VU University
Medical Centre. Standardized assessment included medical history,
neurologic examination, laboratory tests, neuropsychologic testing
including Mini-Mental State Examination (MMSE),14 electroen-
cephalography, and MRI of the brain. Diagnoses were made in a
multidisciplinary consensus meeting according to the Petersen cri-
teria.1 The study was approved by the local medical ethics commit-
tee. All patients gave written, informed consent for their clinical data
to be used for research purposes.
Clinical Follow-Up
All patients were annually re-examined for possible alteration in
cognitive function with a mean follow-up of 21 years. Standard-
ized assessment included careful history and cognitive testing. All
patients in this study were re-evaluated at least once (maximum, 5).
Patients with stable or improved cognitive function at follow-up
were regarded as nonconverters. Patients who progressed to demen-
tia were regarded as converters. Converters were classified in 2
clusters. One cluster included patients who progressed to AD. The
other cluster consisted of patients who progressed to a non-Alzhei-
mer dementia, including vascular dementia (VaD), frontotemporal
lobar degeneration (FTLD), and dementia with Lewy bodies (DLB).
To diagnose AD, we used the criteria of the National Institute on
Neurological and Communicative Diseases and Stroke-Alzheimer
Disease and Related Disorders Association.15 VaD was diagnosed by
use of the criteria of the National Institute of Neurological Disorders
and Stroke-Association Internationale pour la Recherche´ et
l’Enseignement en Neurosciences (NINDS-AIREN),16 FTLD was
diagnosed by the Neary and Snowden criteria,17 and DLB was
diagnosed by the McKeith criteria.18
MRI Protocol
At baseline, MRI was performed on a 1.0-T machine (Magnetom
Impact Expert Siemens AG, Erlangen, Germany) according to a
standard protocol, including coronal T1-weighted 3D magnetization
prepared rapid acquisition gradient echo (168 slices; field of
view250 mm; matrix256256; slice thickness1.5 mm; echo
time7 ms; repetition time15 ms; inversion time300 ms; flip
angle5°); axial fluid-attenuated inversion recovery (FLAIR; 17
slices; field of view250 mm; matrix256256; slice thick-
ness5 mm; interslice gap1.5 mm; echo time105 ms; repetition
time9000 ms; inversion time2200 ms; flip angle180°), and
axial T2*-weighted gradient echo sequences (19 slices; field of
view250 mm; matrix256256; slice thickness5 mm; interslice
gap1.5 mm; echo time22 ms; repetition time800 ms; flip
angle20°).
Image Assessment
Baseline MRI was used to determine the presence of atrophy and
vascular disease. Visual rating of MTA was performed on coronal
T1-weighted images according to the 5-point (0–4) Scheltens scale
from the average score of the left and right sides.19 Global cortical
atrophy was assessed visually on axial FLAIR images (possible
range of scores 0 to 3).20 The degree of WMH severity was rated on
axial FLAIR images on a semiquantitative scale.21 Periventricular
and deep WMHs (DWMHs) were rated separately, the rating for
each score being based on both size and number of lesions in
different anatomic regions. Periventricular hyperintensities (PVHs)
were defined as lesions adjacent to the lateral ventricles or the
occipital or frontal horns resulting in a score ranging from 0 to 6.
DWMHs were defined as lesions located in the frontal, parietal,
occipital, and temporal deep white matter with a maximum score of
6 for each region to give a total score ranging from 0 to 24. A total
WMH score was composed by summing the PVH and DWMH
scores, ranging from 0 to 30. Ratings of basal ganglia and infraten-
torial hyperintensities were not included in the present study.
Lacunes were defined as T1-hypointense and T2-hyperintense cere-
brospinal fluid–like lesions surrounded by white matter or subcorti-
cal gray matter with a minimum diameter of 3 mm, not located in
areas with a high prevalence of widened perivascular spaces (vertex,
anterior commissure). Next to an overall count of lacunes, the
presence of 1 lacune in the basal ganglia was determined. Microb-
leeds were defined as strongly hypointense, mostly round lesions on
the axial FLASH 2D images with a diameter between 2 and 10 mm.
Symmetrical hypointensities in the globi pallidi, most likely to be
calcification or iron deposition, and flow void artifacts of the pial
blood vessels were disregarded. The presence of infarcts was
determined from the different MRI sequences.
Statistical Analysis
Statistical analysis was performed with SPSS 14.0 (SPSS Inc). For
analyzing purposes, MRI measures were dichotomized, with the
median score of the total population for the WMH measurements.
This resulted in the following categories: severe MTA: 1.5 absent,
1.5 present; severe PVH: 3 absent, 3 present; severe DWMH:
4 absent, 4 present; severe WMH: 6 absent, 6 present;
presence of 1 lacune, presence of 1 microbleed, presence of 1
infarct. Group comparisons were performed with 2 tests for dichot-
omous variables and independent samples t tests for continuous data.
Next, Cox proportional-hazards models, which account for varying
follow-up times, were used to investigate the risk of progression to
dementia depending on the various dichotomized MRI measures.
The analysis was performed twice, first using progression to AD as
the outcome measure with the nonconverters as a reference group.
Subsequently, progression to a non-Alzheimer dementia was ana-
lyzed as a second outcome measure, with the nonconverters again as
a reference group. Data are presented as hazard ratio (HR) and
accompanying 95% CI. The first model shows the crude risk
estimates. In the second model, we adjusted for age and sex.
Significance was set at P0.05.
Results
Of the total 152 MCI patients, 72 (47%) progressed to
dementia during follow-up. Fifty-six patients (37%) were
diagnosed with AD, and 16 patients (10%) were diagnosed
with a non-Alzheimer dementia (VaD n7, FTLD n5, DLB
n2, Parkinson dementia n1, alcohol dementia n1).
Converters had a slightly longer follow-up duration and were
older, were more likely to be female, and had a lower MMSE
at baseline (Table 1).
Baseline MRI measures are presented in Table 2. Both
patients who progressed to AD and those who progressed to
a non-Alzheimer dementia showed more MTA and more
cortical atrophy than did nonconverters. Measures of vascular
disease were more prevalent among patients who progressed
to non-Alzheimer dementia compared with nonconverters:
the severity of WMHs (both PVHs and DWMHs) was higher
in patients who progressed to a non-Alzheimer dementia
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compared with nonconverters. In addition, these patients
more often had lacunes in the basal ganglia and microbleeds.
Cox proportional-hazard models showed that, adjusted for
age and sex, baseline MTA predicted progression to AD
(HR2.9; 95% CI, 1.7 to 5.3; Table 3). None of the measures
of vascular disease predicted progression to AD. A different
picture emerged for progression to non-Alzheimer dementia.
Adjusted for age and sex, severe WMHs (HR5.8, 95% CI,
1.2 to 26.6) were strongly associated with progression to
non-Alzheimer dementia. This association was attributable to
both PVHs (HR6.5; 95% CI, 1.4 to 29.8; eg, see Figure 1)
and DWMHs (HR5.7, 1.2 to 26.7), with the highest risk for
PVHs. Furthermore, the presence of microbleeds conferred
an almost 3-fold, though still nonsignificant, increased risk of
progression to non-Alzheimer dementia (HR2.6; 95% CI,
0.9 to 7.5). The same was seen for the presence of lacunes in
the basal ganglia, which showed a 2-fold, though nonsig-
nificant, predictive value on progression to non-Alzheimer
dementia (HR2.4; 95% CI, 0.8 to 7.5). These results
remained essentially unchanged after additional adjustment
for MTA or MMSE (data not shown). Moreover, MTA
showed a 2-fold, though nonsignificant increased risk for
progression to non-Alzheimer dementia (HR2.5; 95% CI,
0.8 to 7.2; eg, see Figure 2).
Discussion
We showed that in MCI patients, MTA and markers of
cerebrovascular disease predicted progression to different
types of dementia. MTA was a risk factor for progression
from MCI to AD, while conversely the presence of cerebro-
vascular disease was independently associated with progres-
sion of MCI to a non-Alzheimer dementia, mostly VaD.
The role of atrophy in progression to dementia has been
shown before. Earlier reports already noted visual assessment
of MTA as good predictor of progression of MCI to demen-
tia.4–6 MTA has been shown to be present not only in patients
with AD but also in other dementias (like VaD and
DLB).22–24 This is in line with our noticeable, though non-
significant, 2-fold, increased risk of MTA for progression
to a non-Alzheimer dementia.
There has been growing interest lately in the possible
influence of vascular factors in the development of AD.
Vascular risk factors, like hypertension and diabetes, have
been associated with an elevated risk of AD, and AD patients
have been reported to show more vascular abnormalities on
MRI than controls.25–29 Contrary to our expectation, we did
not find any relation between the presence of cerebrovascular
disease on baseline MRI and progression to AD. With respect
to WMHs, this is in line with some9,11 but not all10 previous
reports. However, the latter study was small and used
computed tomography instead of MRI.10 Although we found
no influence of WMHs on progression from MCI to AD,
progression to non-Alzheimer dementia was strongly associ-
ated with both PVHs and DWMHs, with the highest risk
attributable to PVHs. These findings confirm the recently
Table 1. Baseline Characteristics
Nonconverters Converters AD Non-Alzheimer Dementia
Patients, n (%) 80 (53%) 72 (47%) 56 (37%) 16 (10%)
Follow-up duration, y 1.8 (1.1) 2.2 (1.3)† 2.2 (1.3) 2.2 (1.4)
Age, y 68 (9) 72 (7)‡ 72 (7)† 75 (6)‡
Women, n (%) 31 (39%) 40 (56%)† 33 (59%)† 7 (44%)
MMSE at baseline 27 (2) 26 (2)‡ 26 (2)‡ 27 (2)
MMSE at follow-up* 27 (2) 20 (5)§ 20 (5)§ 21 (5)‡
Data are presented as mean (SD) or n (%). Comparison of data by 2 or t test when appropriate, with the nonconverters as the
reference group.
*Available for 113 patients.
Compared with nonconverters: †P0.05; ‡P0.01; §P0.001.
Table 2. Baseline MRI Characteristics
Nonconverters Converters AD Non-Alzheimer Dementia
MTA 0.7 (0.8) 1.4 (0.9)§ 1.4 (1.0)§ 1.2 (0.8)‡
Cortical atrophy 0.6 (0.7) 1.0 (0.8)‡ 1.0 (0.7)‡ 1.2 (0.9)‡
PVHs 2.3 (1.7) 2.9 (1.6) 2.6 (1.5) 3.8 (1.5)‡
DWMHs 4.9 (5.4) 5.4 (5.2) 4.4 (4.6) 8.9 (5.6)‡
Total WMHs 7.1 (6.9) 8.3 (6.5) 6.9 (5.9) 12.7 (6.9)‡
Presence of 1 lacune, n (%) 15 (19%) 15 (21%) 10 (18%) 5 (31%)
Presence of 1 lacune BG, n (%) 9 (11%) 13 (18%) 8 (14%) 5 (31%)†
Presence of 1 MB, n (%)* 11 (15%) 10 (16%) 4 (9%) 6 (38%)†
Presence of 1 infarct, n (%) 5 (6%) 4 (6%) 3 (5%) 1 (6%)
MB indicates microbleed; BG, basal ganglia. Data are presented as mean (SD) unless otherwise specified. Comparison of data by
2 or t test when appropriate with the nonconverters as the reference group.
*Missing nonconverters n5, AD n9.
Compared with nonconverters: †P0.05; ‡P0.01; §P0.001.
Staekenborg et al Progression of MCI to Dementia 1271
reported predictive value of DWMHs and especially PVHs
for vascular or mixed dementia.11 Others did not find a
predictive value of WMHs for progression to non-Alzheimer
dementia.7,9 Nonetheless, in both of these last-mentioned
studies, the number of patients was small (3 and 7 patients,
respectively). We had a sample of 16 patients who progressed
to a non-Alzheimer dementia. Of these, the largest subgroup
consisted of VaD. Still, the effect did not seem attributable to
this group alone, because in patients with Parkinson demen-
tia, DLB, and alcohol dementia especially, we observed
vascular disease as well. We are not sure how to interpret this
finding. It is known that cerebrovascular disease can cause
parkinsonism.30 Alternatively, it must be noted that diagnosis
was based on clinical criteria, leaving the possibility of mixed
disease. Unfortunately, the sample size did not allow examina-
tion of progression to specific dementia types other than AD.
We demonstrated that the prevalence of lacunes in the
basal ganglia was higher in patients who progressed to
non-Alzheimer dementia compared with nonconverters. A
population-based study showed that silent mostly lacunar
brain infarcts were a risk factor for dementia.29 Other reports
in MCI patients did not find an association between lacunes
and progression to dementia.9,31 In this study, Cox analysis of
Table 3. Cox Regression Analysis
AD Non-Alzheimer Dementia
Model 1 Model 2 Model 1 Model 2
MTA 2.9 (1.7–5.0) 2.9 (1.7–5.3) 2.9 (1.1–7.9) 2.5 (0.8–7.2)
GCA 1.6 (0.8–3.1) 1.4 (0.7–2.7) 2.4 (0.8–7.0) 2.2 (0.7–7.0)
PVHs 1.3 (0.7–2.2) 1.1 (0.7–2.0) 7.3 (1.7–32.4) 6.5 (1.4–29.8)
DWMHs 1.4 (0.8–2.4) 1.3 (0.8–2.3) 5.7 (1.3–25.5) 5.7 (1.2–26.7)
Total WMHs 1.3 (0.8–2.2) 1.2 (0.7–2.2) 6.0 (1.3–26.8) 5.8 (1.2–26.6)
Lacunes 1.2 (0.6–2.4) 1.1 (0.5–2.2) 2.3 (0.8–6.8) 2.1 (0.7–6.4)
Lacunes basal ganglia 1.4 (0.7–3.0) 1.2 (0.6–2.6) 2.7 (0.9–8.1) 2.4 (0.8–7.5)
Microbleeds 0.7 (0.3–2.0) 0.8 (0.2–2.2) 2.5 (0.9–7.2) 2.6 (0.9–7.5)
Infarcts 0.8 (0.3–2.6) 1.1 (0.3–3.8) 0.8 (0.1–6.6) 1.4 (0.2–12.1)
MTA indicates medial temporal lobe atrophy; GCA, global cortical atrophy. Data are presented as HR (95% CI). Cox regression
analysis compared progression to AD and non-Alzheimer dementia with nonconverters. The first model was unadjusted; the second
model was adjusted for age and sex.
Figure 1. Axial FLAIR image of a patient diagnosed after 1 year
of follow-up with DLB, showing beginning confluent WMHs
mainly around the ventral and occipital horns of the lateral ven-
tricles. Additionally, this patient showed a lacune in the nucleus
caudatus and 2 microbleeds (images not shown).
Figure 2. Coronal T1-weighted image of a patient diagnosed
after 2 years of follow up with VaD, showing an MTA score of 2
on the left and the right side. In addition, this patient showed
confluent WMHs, 2 lacunes (paraventricular and basal ganglia
left hemisphere), and 1 microbleed (images not shown).
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lacunes in the basal ganglia was, although borderline signif-
icant; suggestive of a 2-fold elevated risk of progression to
a non-Alzheimer dementia. We did not find a predictive value
of large-vessel infarcts on progression of MCI to dementia.
Although having a (large-vessel) stroke is known to double
the risk of dementia,32 in MCI patients the absence of
progression related to infarcts has been reported before.9 A
study in patients with VaD found that patients with multi-
infarct or strategic infarct dementia were predominantly
diagnosed directly from a cognitive normal status, whereas
patients with VaD based on small-vessel disease often go
through a stage of MCI.33
Our study showed that the prevalence of microbleeds was
higher in patients who progressed to a non-Alzheimer demen-
tia compared with nonconverters. Furthermore, the presence
of microbleeds showed an almost 3-fold, borderline signifi-
cant risk for progression to a non-Alzheimer dementia. Little
research has been performed on the role of microbleeds in
MCI patients and on microbleeds in relation to cognitive
dysfunction. A study in 86 patients with subcortical VaD
found microbleeds to be related to all cognitive domains with
the exception of language function.12 Another study in
nondemented patients with cerebrovascular disease found a
relation between microbleeds and executive dysfunction.13
Microbleeds are presumed to reflect cerebral amyloid angi-
opathy, a type of cerebrovascular pathology found with an
incidence of 80% to 98% in AD.34,35 In the current study, we
did not find a higher prevalence of microbleeds and patients
who progressed to AD compared with nonconverters. None-
theless, our results suggest that microbleeds are a risk factor
for progression to a non-Alzheimer dementia.
Among the limitations of this study is the use of visual
rating scales of MRI markers. Volumetric measures of MTA
and WMHs could lead to different effect sizes, at the cost of
being less generalizable to clinical practice. A complex issue
is the role of MRI in the follow-up diagnosis, even though the
diagnosis of dementia basically is a clinical diagnosis. At
baseline none of the patients fulfilled the clinical criteria of
dementia, and progression to dementia itself will not have
been influenced by the MRI scan. In assessing the specific
dementia types, MRI may have been used as a supportive
element and therefore may have induced some circularity.
This is especially the case for VaD, as current criteria require
evidence of cerebrovascular disease on imaging.16 Any study
assessing the risk of progression to at least VaD might
consequently suffer from some degree of circularity. How-
ever, we think that the influence of this circularity is limited,
as the clinical diagnosis of the specific dementia types was
fundamentally based on the clinical picture and not on MRI.
Unfortunately, we have no neuropathologic confirmation of
our diagnoses, and it must be noted that patients with
dementia frequently have shown multiple brain pathologies.36
We demonstrated in this study that patients with vascular
abnormalities on baseline MRI were more likely to develop
non-Alzheimer dementia, mostly VaD. Still, it is conceivable
that a large proportion of patients in fact suffered from mixed
disease. Future research incorporating neuropathologic con-
firmation is needed to answer this question. Another limita-
tion is the absence of clinical characterization of the MCI
cases into subgroups (amnestic/nonamnestic, single domain/
multiple domain).37 The clinical subtype may be related to the
type of dementia (AD vs non-Alzheimer dementia) a MCI
patient is most likely to progress to. Future research should be
aimed to find out if the MRI determinations (of atrophy and
cerebrovascular disease) add predictive value over this clin-
ical MCI characterization.
Compared with the conversion rate of 12% per year
reported by Petersen et al,1 the conversion rate of almost 25%
in our group of MCI patients seems rather high. However, our
results are comparable to the conversion rate of other memory
clinics,38,39 whereas the conversion rate reported by Petersen
et al1 was found in a general community setting.
A strong element is the exploration of the influence of a
broad range of vascular abnormalities on MRI, including
infarcts, WMHs, lacunes, and microbleeds. We adjusted
analyses for age and sex and additionally for MMSE and
MTA without essential change in the results. Furthermore, we
included more MCI patients than most previous reports,
including a considerable number of patients who progressed
to non-Alzheimer dementia. However, the group of 16
patients was not large enough to allow examination of
progression to specific dementia types other than AD. To
conclude, in the clinical setting of a memory clinic, one
should be aware of cerebrovascular disease, as it appears to
be an important predictor of progression to non-Alzheimer
dementia.
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